Cited by 301Hormonal Regulation and HypertensionRenin-Angiotensin System StudiesBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Characterization of Resistant Hypertension<subtitle>Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion</subtitle>

Open access

Gaddam, Krishna K.·2008·Archives of Internal Medicine

DOI 10.1001/archinte.168.11.1159PMC PMC2748247

Open this paper in CoChat — free account

Abstract

BACKGROUND: Resistant hypertension is a common clinical problem and greatly increases the risk of target organ damage. METHODS: We evaluated the characteristics of 279 consecutive patients with resistant hypertension (uncontrolled despite the use of 3 antihypertensive agents) and 53 control subjects (with normotension or hypertension controlled by using <or=2 antihypertensive medications). Participants were prospectively examined for plasma aldosterone concentration, plasma renin activity, aldosterone to renin ratio, brain-type natriuretic peptide, atrial natriuretic peptide, and 24-hour urinary aldosterone (UAldo), cortisol, sodium, and potassium values while adhering to a routine diet. RESULTS: Plasma aldosterone (P < .001), aldosterone to renin ratio (P < .001), 24-hour UAldo (P = .02), brain-type natriuretic peptide (P = .007), and atrial natriuretic peptide (P = .001) values were higher and plasma renin activity (P = .02) and serum potassium (P < .001) values were lower in patients with resistant hypertension vs controls. Of patients with resistant hypertension, men had significantly higher plasma aldosterone (P = .003), aldosterone to renin ratio (P = .02), 24-hour UAldo (P < .001), and urinary cortisol (P < .001) values than women. In univariate linear regression analysis, body mass index (P = .01), serum potassium (P < .001), urinary cortisol (P < .001), urinary sodium (P = .02), and urinary potassium (P < .001) values were correlated with 24-hour UAldo levels. Serum potassium (P = .001), urinary potassium (P < .001), and urinary sodium (P = .03) levels were predictors of 24-hour UAldo levels in multivariate modeling. CONCLUSIONS: Aldosterone levels are higher and there is evidence of intravascular volume expansion (higher brain-type and atrial natriuretic peptide levels) in patients with resistant hypertension vs controls. These differences are most pronounced in men. A significant correlation between 24-hour urinary aldosterone levels and cortisol excretion suggests that a common stimulus, such as corticotropin, may underlie the aldosterone excess in patients with resistant hypertension.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archinte.168.11.1159

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000
Hajjar, I. M. (2003) · JAMA · doi:10.1001/jama.290.2.199 · Cited by 2,399
A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease
Pepine, C. J., Handberg, E. M., Cooper‐DeHoff, R. M., Marks, R. G., Kowey, P. R., Messerli, F. H., Mancia, G., Cangiano, J. L., García-Barreto, D., Keltai, M., et al. (2003) · JAMA · doi:10.1001/jama.290.21.2805 · Cited by 1,278
Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.02045.x · Cited by 979
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B., & Weissmann, P. (2002) · Hypertension · doi:10.1161/01.hyp.0000040261.30455.b6 · Cited by 763
Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial
Black, H. R. (2003) · JAMA · doi:10.1001/jama.289.16.2073 · Cited by 741
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
Chapman, N., Dobson, J., Wilson, S. L., Dahlöf, B., Sever, P., Wedel, H., & Poulter, N. R. (2007) · Hypertension · doi:10.1161/01.hyp.0000259805.18468.8c · Cited by 630
Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons
Vasan, R. S., Evans, J. C., Larson, M. G., Wilson, P. W. F., Meigs, J. B., Rifai, N., Benjamin, E. J., & Levy, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033263 · Cited by 573
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 500

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 1

[19]Gomez-Sanchez CE. Adrenal steroid synthesis and regulation. In: Izzo JL, Black HR, editors. Hypertension primer. Liipincott Williams & Wilkins; Philadelphia: 2003. [Google Scholar]

Sorted by citations

Items 101–200 of 300

Global- and Renal-Specific Sympathoinhibition in Aldosterone Hypertension
Lohmeier, T. E., Liu, B., Hildebrandt, D. A., Cates, A. W., Georgakopoulos, D., & Irwin, E. D. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05155 · Cited by 29
Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study
Yano, Y., Hoshide, S., Tamaki, N., Nagata, M., Sasaki, K., Kanemaru, Y., Shimada, K., & Kario, K. (2011) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310390404 · Cited by 29
Mineralocorticoid Receptor Blockade in Chronic Kidney Disease
Bomback, A. S., & Klemmer, P. J. (2012) · Blood Purification · doi:10.1159/000334161 · Cited by 28
Assessment of Mean Platelet Volume in Patients with Resistant Hypertension, Controlled Hypertension and Normotensives
Sürgit, Ö., Püşüroğlu, H., Ertürk, M., Akgül, Ö., Buturak, A., Akkaya, E., Gül, M., Uygur, B., Yazan, S., & Eksik, A. (2015) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2015.43 · Cited by 28
Resistant Hypertension in Nondialysis Chronic Kidney Disease
Borrelli, S., Nicola, L. D., Stanzione, G., Conte, G., & Minutolo, R. (2013) · International Journal of Hypertension · doi:10.1155/2013/929183 · Cited by 27
Adiponectin ‐11377C/G and +276G/T Polymorphisms affect Adiponectin Levels but do not Modify Responsiveness to Therapy in Resistant Hypertension
de Faria, A. P., Modolo, R., Sabbatini, A. R., Barbaro, N. R., Corrêa, N. B., Brunelli, V., Tanus-Santos, J. E., Fontana, V., & Moreno, H. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12368 · Cited by 27
Posicionamento Brasileiro sobre Hipertensão Arterial Resistente – 2020
Yugar‐Toledo, J. C., Moreno, H., Gus, M., Rosito, G. B. A., Scala, L. C. N., Muxfeldt, E. S., Alessi, A., Brandão, A. A., Filho, O. M., Feitosa, A. D. M., et al. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200198 · Cited by 33
Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype
Rouby, N. M. E., & Cooper‐DeHoff, R. M. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0583-8 · Cited by 27
Hypertension in African Populations: Review and Computational Insights
Mabhida, S. E., Mashatola, L., Kaur, M., Sharma, J. R., Apalata, T. R., Muhamed, B., Benjeddou, M., & Johnson, R. (2021) · Genes · doi:10.3390/genes12040532 · Cited by 26
A role for single-pill triple therapy in hypertension
Elijovich, F., & Laffer, C. L. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709334947 · Cited by 26
Treatment of systemic hypertension in children and adolescents
Garin, E. H., & Araya, C. E. (2009) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32832ff3a7 · Cited by 26
Resistant Hypertension
Carey, R. M. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00601 · Cited by 28
Epidemiology of Resistant Hypertension in Canada
Leung, A. A. C., Williams, J. V. A., Tran, K. C., & Padwal, R. S. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.01.029 · Cited by 25
Primary aldosteronism: Higher volume load, cardiac output and arterial stiffness than in essential hypertension
Choudhary, M. K., Värri, E. K. H., Matikainen, N., Koskela, J., Tikkakoski, A., Kähönen, M. A. P., Niemelä, O. J., Mustonen, J. T., Nevalainen, P. I., & Pörsti, I. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13115 · Cited by 25
Treatment of resistant hypertension
Pimenta, E., & Calhoun, D. A. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833eafa3 · Cited by 25
Clinical situations associated with difficult-to-control hypertension
Oliveras, A., & Schmieder, R. E. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835d2af0 · Cited by 24
Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance
Calhoun, D. A. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.5.593 · Cited by 23
Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies
Pappaccogli, M., Covella, M., Berra, E., Fulcheri, C., Monaco, S. D., Perlo, E., Burrello, J., Monticone, S., Rossato, D., Rabbia, F., et al. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0260-5 · Cited by 24
Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study
Romano, S. L., Idolazzi, C., Fava, C., Fondrieschi, L., Celebrano, M., Delva, P., Branz, L., Donato, A. D., Dalbeni, A., & Minuz, P. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0268-x · Cited by 23
Special Article - The management of resistant hypertension: A 2020 update
Carey, R. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.08.001 · Cited by 23
Resistant or Refractory Hypertension: Are They Different?
Modolo, R., de Faria, A. P., Almeida, A. R., & Moreno, H. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0485-1 · Cited by 22
Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study
on behalf of the Spanish Sleep Network, Navarro‐Soriano, C., Martínez‐García, M. Á., Torres, G., Barbé, F., Caballero‐Eraso, C., Lloberes, P., Díaz-Cambriles, T., Somoza, M., Masa, J. F., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0285-8 · Cited by 21
Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
Sidharta, P. N., Ulč, I., & Dingemanse, J. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00837-x · Cited by 22
Definition, identification and treatment of resistant hypertension in chronic kidney disease patients
Drexler, Y. R., & Bomback, A. S. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft346 · Cited by 21
Drug Therapy of Apparent Treatment-Resistant Hypertension: Focus on Mineralocorticoid Receptor Antagonists
Glicklich, D., & Frishman, W. H. (2015) · Drugs · doi:10.1007/s40265-015-0372-3 · Cited by 21
Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels
Holland Nephrology Study (HONEST) Network, Gant, C. M., Laverman, G. D., Vogt, L., Slagman, M. C. J., Heerspink, H. J. L., Waanders, F., Hemmelder, M. H., & Navis, G. J. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0789-x · Cited by 22
Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement
Faconti, L., George, J., Partridge, S., Maniero, C., Sathyanarayanan, A., Kulkarni, S., Kapil, V., Petrosino, A., Lewis, P., McCormack, T., et al. (2024) · Journal of Human Hypertension · doi:10.1038/s41371-024-00983-6 · Cited by 23
Prevalencia de lesión de órganos diana y alteraciones metabólicas en la hipertensión arterial refractaria
Armario, P., Oliveras, A., del Rey, R. H., Ruilope, L. M., & de la Sierra, A. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.02.035 · Cited by 20
Hypertension: Issues in control and resistance
Wofford, M. R., & Minor, D. S. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0055-0 · Cited by 20
T allele of −344C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension
Lacchini, R., Sabha, M., Coeli, F. B., Favero, F. F., Yugar‐Toledo, J. C., Izidoro‐Toledo, T. C., Sandrim, V. C., Tanus-Santos, J. E., de Mello, M. P., & Moreno, H. (2009) · Hypertension Research · doi:10.1038/hr.2008.36 · Cited by 20
Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status
Ghazi, L., Dudenbostel, T., Lin, C. P., Oparil, S., & Calhoun, D. A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000870 · Cited by 19
Resistant hypertension: Diagnosis, evaluation, and treatment practical approach
Parodi, R., Brandani, L., Romero, C. R., & Klein, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.12.026 · Cited by 20
Ambulatory Blood Pressure and Adherence Monitoring: Diagnosing Pseudoresistant Hypertension
Burnier, M., & Wuerzner, G. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.003 · Cited by 18
Resistance to antihypertensive treatment and long‐term risk: The Atherosclerosis Risk in Communities study
Wijkman, M. O., Malachias, M. V. B., Claggett, B. L., Cheng, S. C., Matsushita, K., Shah, A. M., Jhund, P. S., Coresh, J., Solomon, S. D., & Vardeny, O. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14269 · Cited by 18
Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation
Azzam, O., Nejad, S. H., Carnagarin, R., Nolde, J. M., Kiuchi, M. G., & Schlaich, M. P. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16247 · Cited by 21
Resistant Hypertension: Where are We Now and Where Do We Go from Here?
Pathan, M. K., & Cohen, D. L. (2020) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s223334 · Cited by 22
Neuroadrenergic disarray in pseudo-resistant and resistant hypertension
Grassi, G. M., Bombelli, M., Buzzi, S., Volpe, M., & Brambilla, G. (2014) · Hypertension Research · doi:10.1038/hr.2014.25 · Cited by 18
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24
Flack, J. M., Azizi, M., Brown, J. M., Dwyer, J. P., Jones, E. S. W., Lihn, A. S., Liu, L., Olsson, D. S., Perl, S., Shibata, H., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02297-7 · Cited by 19
Management of Resistant Hypertension
Lauder, L., Mahfoud, F., & Böhm, M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050922-052605 · Cited by 16
Drug Mechanisms to Help in Managing Resistant Hypertension in Obesity
Jansen, P. M., Danser, J., Spiering, W., & van den Meiracker, A. H. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0123-5 · Cited by 17
Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension
Kisaka, T., Ozono, R., Ishida, T., Higashi, Y., Oshima, T., & Kihara, Y. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e328359862d · Cited by 17
An increased visceral–subcutaneous adipose tissue ratio is associated with difficult-to-treat hypertension in men
Ishikawa, J., Haimoto, H., Hoshide, S., Eguchi, K., Shimada, K., & Kario, K. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328338158b · Cited by 17
Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?
Yugar-Toledo, J., Brunelli, V., Vilela-Martin, J. F., Fattori, A., & Moreno, H. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0825-7 · Cited by 18
Diagnosis and Management of Resistant Hypertension
Azizi, M., Vongpatanasin, W., Fisher, N. D. L., Mahfoud, F., Amar, L., & Kirtane, A. J. (2026) · JAMA · doi:10.1001/jama.2026.1221 · Cited by 19
Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension
Ritter, A. M. V., Fontana, V., de Faria, A. P., Modolo, R., Barbaro, N. R., Sabbatini, A. R., Peres, H. A., Biagi, C., Silva, P. S., Lopes, P. C., et al. (2015) · American Journal of Hypertension · doi:10.1093/ajh/hpv070 · Cited by 16
Aldosterone receptor antagonists
Azizi, M. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.03.009 · Cited by 20
Salt and Aldosterone
Acelajado, M. C., Pimenta, E., & Calhoun, D. A. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.160960 · Cited by 16
Resistant Hypertension
Townsend, R. R., & Epstein, M. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07316 · Cited by 15
New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis
Mahfooz, K., Najeed, S. A., Tun, H. N., Khamosh, M., Grewal, D., Hussain, A., Ong, K., Dharmarajan, L., & Vasavada, A. M. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101686 · Cited by 15
Left Heart Morphology and Function in Primary Aldosteronism
Milan, A., Magnino, C., Fabbri, A., Chiarlo, M., Bruno, G., Losano, I., & Veglio, F. (2012) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/11593690-000000000-00000 · Cited by 15
Prescribing patterns in the treatment of hypertension among underserved African American elderly.
Yazdanshenas, H., Bazargan, M., Orum, G., Loni, L., Mahabadi, N., & Husaini, B. A. (2014) · PubMed · Cited by 15
Relationship of Resistant Hypertension and Treatment Outcomes With Total Arterial Compliance in a Predominantly African American Hypertensive Cohort
Bakhtar, O., Ference, B. A., Hedquist, L. A., Levy, P. D., & Flack, J. M. (2012) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00653.x · Cited by 14
MCP-1 Levels are Associated with Cardiac Remodeling but not with Resistant Hypertension
Ritter, A. M. V., de Faria, A. P., Sabbatini, A. R., Corrêa, N. B., Brunelli, V., Modolo, R., & Moreno, H. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170033 · Cited by 14
Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial
Engholm, M., Bertelsen, J. B., Mathiassen, O. N., Bøtker, H. E., Vase, H. Ø., Peters, C. D., Bech, J. N., Buus, N. H., Schroeder, A. P., Rickers, H., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.09.200 · Cited by 14
Epidemiology, Prognosis, and Treatment of Resistant Hypertension
Smith, S. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1297 · Cited by 14
NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism
Pizzolo, F., Zorzi, F., Chiecchi, L., Consoli, L., Aprili, I., Guarini, P., Castagna, A., Salvagno, G. L., Pavan, C., & Olivieri, O. (2013) · Endocrine · doi:10.1007/s12020-013-0028-6 · Cited by 13
Resistant hypertension: Renal denervation or intensified medical treatment?
Morganti, A., & Mancia, G. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.12.010 · Cited by 13
Pathogenesis of Hypertension
Acelajado, M. C., Calhoun, D. A., & Oparil, S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2766-1.00002-8 · Cited by 15
Sympathetic Activation in Resistant Hypertension: Theory and Therapy
Oliva, R., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.009 · Cited by 13
Decoding resistant hypertension signalling pathways
Parreira, R. C., Lacerda, L. H. G., Vasconcellos, R., Lima, S. S., Santos, A. K., Fontana, V., Sandrim, V. C., & Resende, R. R. (2017) · Clinical Science · doi:10.1042/cs20171398 · Cited by 13
Sequential Nephron Blockade with Combined Diuretics Improves Diastolic Function in Patients with Resistant Hypertension
Fouassier, D., Blanchard, A., Fayol, A., Bobrie, G., Boutouyrie, P., Azizi, M., & Hulot, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12832 · Cited by 13
The possibility of resistant hypertension during the treatment of hypertensive patients
Nishikawa, T., Omura, M., Saito, J., & Matsuzawa, Y. (2013) · Hypertension Research · doi:10.1038/hr.2013.107 · Cited by 12
Resistant hypertension: current status, future challenges.
Gholamalizadeh, M., Entezari, M. H., Paknahad, Z., Hassanzadeh, A., & Doaei, S. (2014) · Europe PMC (PubMed Central) · Cited by 12
Epidemiologie und Ätiologie der therapieresistenten Hypertonie
Schirpenbach, C., & Reincke, M. (2008) · Der Internist · doi:10.1007/s00108-008-2194-9 · Cited by 12
Fluid retention, aldosterone excess, and treatment of resistant hypertension
Calhoun, D. A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30080-9 · Cited by 11
Unilateral chemical ablation of the adrenal gland lowers blood pressure and alleviates target organ damage in spontaneously hypertensive rats
Wang, X., Luo, T., Yang, Y., Zhou, Y., Hou, J., & Wang, P. (2023) · Hypertension Research · doi:10.1038/s41440-023-01444-2 · Cited by 11
Clinical Diagnosis and Management of Resistant Hypertension
Tsioufis, C. P., Kasiakogias, A., & Tousoulis, D. M. (2016) · European Cardiology Review · doi:10.15420/ecr.2016:1:2 · Cited by 11
Heart failure: the role for mineralocorticoid receptor antagonists
Pitt, B. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13959 · Cited by 11
Uncontrolled Arterial Hypertension: Kidney, Neurohormonal Imbalance, and Approaches to Antihypertensive Drug Therapy
Ob, K., Викторовна, Б. Н., Викторович, Ж. В., & Serdyuk, S. V. (2019) · Kardiologiia · doi:10.18087/cardio.2019.12.n547 · Cited by 11
Efficacy and safety of baroreflex activation therapy for treatment of resistant hypertension: a systematic review and meta-analysis
Wang, C., Fu, S., & Huang, J. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2016.1273943 · Cited by 10
Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis
Bacan, G., Ribeiro-Silva, A., Oliveira, V. A., Cardoso, C. R. L., & Salles, G. F. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01165-w · Cited by 10
Predictive performance of aldosterone-to-renin ratio in the diagnosis of primary aldosteronism in patients with resistant hypertension
Bioletto, F., Lopez, C., Bollati, M., Arata, S., Procopio, M., Ponzetto, F., Beccuti, G., Mengozzi, G., Ghigo, E., Maccario, M., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1145186 · Cited by 10
Update on diagnosis and treatment of resistant hypertension.
Pimenta, E. (2011) · Iranian Journal of Kidney Diseases · Cited by 10
Prevalence and characteristics of apparent treatment-resistant hypertension in older people in China: a cross-sectional study
Wu, C., Wang, Y., Zhang, W., Li, X., Wang, L., & Hui, R. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2018.1545852 · Cited by 10
Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part I
Safaryan, A. S., & Sargsyan, V. D. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2693 · Cited by 12
Role of Sodium Restriction and Diuretic Therapy for “Resistant” Hypertension in Chronic Kidney Disease
Sinnakirouchenan, R., & Kotchen, T. A. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.005 · Cited by 10
Left ventricle remodeling in men with moderate to severe volume-dependent hypertension
Indra, T., Holaj, R., Zelinka, T., Petrák, O., Štrauch, B., Rosa, J., Krátká, Z., Malík, J., Janota, T., Hradec, J., et al. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312446240 · Cited by 10
Atomoxetine and spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients
Schwartz, A. R., Herpel, L. B., Bogan, R., Corser, B. C., Pho, H., & Taranto‐Montemurro, L. (2024) · Sleep And Breathing · doi:10.1007/s11325-024-03113-1 · Cited by 9
Is It Time to Retire Aldosterone Suppression Testing?
Kline, G. A., Leung, A. A. C., Orton, D. J., MacFarlane, J., & Gurnell, M. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf163 · Cited by 9
Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!
Maiolino, G., Azzolini, M., & Rossi, G. P. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00003 · Cited by 9
Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients
Viigimaa, M., Talvik, A., Wojciechowska, W., Kawecka−Jaszcz, K., Toft, I., Stergiou, G. S., Nasothimiou, E. G., Kotsis, V., Rosei, E. A., Salvetti, M., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.782900 · Cited by 9
Plasma endothelin-1 levels in patients with resistant hypertension: effects of renal sympathetic denervation
Petramala, L., Olmati, F., Mancone, M., Concistrè, A., Galassi, M., Marinelli, C., Tonnarini, G., Lucia, P., Costi, U., Iannucci, G., et al. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1282623 · Cited by 9
The Prevalence of Obstructive Sleep Apnea in Patients With Primary Aldosteronism
Sheu, J.-Y., Chang, L., Chen, J., Chuang, M., Wu, V., & Chueh, S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae415 · Cited by 8
Hipertensión arterial, un enemigo peligroso
Soca, P. E. M., & Teruel, Y. S. (2009) · Acimed · Cited by 8
Recent Advancements in the Treatment of Resistant Hypertension
Clark, D., Guichard, J. L., Calhoun, D. A., & Ahmed, M. I. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2519 · Cited by 8
Hyperaldosteronism Screening and Findings From a Large Diverse Population With Resistant Hypertension Within an Integrated Health System
Kim, V., Shi, J. M., An, J., Bhandari, S. K., Brettler, J. W., Kanter, M. H., & Sim, J. J. (2023) · The Permanente Journal · doi:10.7812/tpp/23.096 · Cited by 8
Resistant and refractory arterial hypertension: similarities and differences, new approaches to diagnosis and treatment
Владимировна, А. А., Евгеньевна, Е. Т., Анатольевна, С. О., & Чазова, И. Е. (2018) · Systemic Hypertension · doi:10.26442/2075-082x_2018.3.11-13 · Cited by 8
Controversies in Hypertension V: Resistant and Refractory Hypertension
Filippone, E. J., Naccarelli, G. V., & Foy, A. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.09.015 · Cited by 10
MDR-1 C 3435 T polymorphism may affect blood pressure in resistant hypertensive patients independently of its effects on aldosterone release
Lacchini, R., Figueiredo, V. N., Demacq, C., Coeli‐Lacchini, F. B., Martins, L. C., Yugar‐Toledo, J. C., Coca, A., Tanus-Santos, J. E., & Moreno, H. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312466124 · Cited by 8
Blood Pressure and Renal Responses to Orthostatic Stress Before and After Radiofrequency Renal Denervation in Patients with Resistant Hypertension
Vuignier, Y., Grouzmann, E., Müller, O., Vakilzadeh, N., Faouzi, M., Maillard, M. P., Qanadli, S. D., Burnier, M., & Wuerzner, G. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00042 · Cited by 8
The role of the sympathetic nervous system in resistant hypertension: pathophysiological and clinical aspects
Orekhov, A. Y., & Karazhanova, L. K. (2022) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2022-28-4-348-356 · Cited by 7
Additional drug treatment in resistant hypertension
Mancia, G. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283567338 · Cited by 7
Clinical approach in treatment of resistant hypertension
Frank, J., & Sommerfeld, D. (2009) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s4315 · Cited by 7
Efficacy of nebivolol‐valsartan single‐pill combination in obese and nonobese patients with hypertension
Mende, C. W., Giles, T. D., Bharucha, D. B., Ferguson, W., Mallick, M., & Patel, M. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.12965 · Cited by 7
Aldosterone-to-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met
Kokko, E., Nevalainen, P. I., Choudhary, M. K., Koskela, J., Tikkakoski, A., Huhtala, H., Niemelä, O. J., Viukari, M., Mustonen, J. T., Matikainen, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76718-7 · Cited by 7
Genetic Ablation of Prorenin Receptor in the Rostral Ventrolateral Medulla Influences Blood Pressure and Hydromineral Balance in Deoxycorticosterone-Salt Hypertension
Mathieu, N. M., Fekete, E. M., Muskus, P. C., Brozoski, D., Lu, K., Wackman, K. K., Gomez, J., Fang, S., Reho, J. J., Grobe, C. C., et al. (2023) · Function · doi:10.1093/function/zqad043 · Cited by 6
Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat
Feldman, R. D., Sanjanwala, R., Padwal, R. S., & Leung, A. A. C. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.035 · Cited by 6
Natriuretic Peptides as a Novel Target in Resistant Hypertension
Patel, P. A., & Chen, H. H. (2015) · Current Hypertension Reports · doi:10.1007/s11906-014-0530-0 · Cited by 6
Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension – study protocol for a randomized controlled trial
Cestário, E. D. E. S., Fernandes, L. A. B., Giollo-Júnior, L. T., Uyemura, J. R. R., Matarucco, C. S. S., Landim, M. P., Cosenso‐Martin, L. N., Tácito, L. H. B., Moreno, H., Vilela-Martin, J. F., et al. (2018) · Trials · doi:10.1186/s13063-017-2343-3 · Cited by 6
The Sympathetic Nervous System in Hypertension
Seravalle, G., Mancia, G., & Grassi, G. M. (2018) · Contemporary Endocrinology · doi:10.1007/978-3-319-77048-2_14 · Cited by 7

Authors: Gaddam, K. K.
Affiliations: University of Alabama at Birmingham (US)
Corresponding author: Gaddam, Krishna K.
Venue: Archives of Internal Medicine
Publisher: American Medical Association (AMA)
Published: 2008-06-09
Volume: 168
Issue: 11
Pages: 1159
ISSN: 0003-9926 (ISSN-L)
DOI: 10.1001/archinte.168.11.1159
PMC: PMC2748247
OpenAlex: W2118344567
Cited by: 301
References: 32
Citations by year: 2026: 16 · 2025: 10 · 2024: 9 · 2023: 18 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 13 · 2018: 19 · 2017: 21 · 2016: 20 · 2015: 19 · 2014: 21 · 2013: 24 · 2012: 22
FWCI: 13.02
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Archives of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Heart, Lung, and Blood Institute (HL-007457, HL077100, HL-075614, R01HL075614, P50HL077100, T32HL007457)
National Center for Research Resources (M01RR00032, M01RR000032)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: resistant hypertension, plasma aldosterone, aldosterone-renin ratio, plasma renin activity, brain natriuretic peptide, atrial natriuretic peptide, intravascular volume expansion, urinary cortisol, serum potassium, urinary sodium, sex differences, body mass index, target organ damage, aldosterone excess
MeSH terms: Aldosterone, Antihypertensive Agents, Drug Resistance, Female, Humans, Hydrocortisone, Hypertension, Male, Middle Aged, Atrial Natriuretic Factor, Potassium, Regression Analysis, Renin, Sex Factors, Sodium, Case-Control Studies, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characterization of Resistant Hypertension<subtitle>Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion</subtitle>

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks